<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02151695</url>
  </required_header>
  <id_info>
    <org_study_id>mEdICARE</org_study_id>
    <nct_id>NCT02151695</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy.</brief_title>
  <official_title>Phase 2 Study of Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <brief_summary>
    <textblock>
      Proliferative diabetic retinopathy is a serious complication of diabetes mellitus, partly&#xD;
      consecutive to upregulation of vascular endothelial growth factor (VEGF) as a consequence of&#xD;
      retinal ischemia leads. Aflibercept has been approved by FDA and European medicine agency for&#xD;
      treatment of exudative age-related macular degeneration, another retinal disease&#xD;
      characterized by choroidal new vessels.&#xD;
&#xD;
      The aim of this pilot study is to evaluate the efficacy and the safety of Aflibercept&#xD;
      intravitreal injections compared to panretinal photocoagulation for proliferative diabetic&#xD;
      retinopathy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Actual">March 6, 2020</completion_date>
  <primary_completion_date type="Actual">October 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with regression of retinal neovascularization between baseline and 12th month.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Naive Patients With Uncomplicated Proliferative Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Panretinal photocoagulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aflibercept intravitreal injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>panretinal photocoagulation</intervention_name>
    <arm_group_label>Panretinal photocoagulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept intravitreal injections</intervention_name>
    <arm_group_label>Aflibercept intravitreal injections</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with diabetes mellitus type 1 or type 2 complicated by PDR&#xD;
&#xD;
          -  Male or female over 18 years&#xD;
&#xD;
          -  HbA1c &lt;11.6% at study entry&#xD;
&#xD;
          -  Systolic blood pressure &lt;160 mmHg and diastolic blood pressure &lt;105 mmHg at study&#xD;
             entry&#xD;
&#xD;
          -  Backgrounds clear eye, pupil dilation and patient cooperation sufficient to allow&#xD;
             examination or fundus photographs of good quality&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to aflibercept or to any of the excipients&#xD;
&#xD;
          -  History of retinal laser (macular or panretinal photocoagulation), of intravitreal&#xD;
             injections, of vitrectomy in the eye studied&#xD;
&#xD;
          -  PDR associated with tractional retinal detachment in the eye studied&#xD;
&#xD;
          -  PDR associated with fibrovascular proliferation in the eye studied&#xD;
&#xD;
          -  Florid diabetic retinopathy&#xD;
&#xD;
          -  Eye infection or periocular active or suspected&#xD;
&#xD;
          -  Unbalanced glaucoma in the eye studied&#xD;
&#xD;
          -  Other eye disease in the eye studied&#xD;
&#xD;
          -  Patients with significant medical problems that may interfere with the evaluation of&#xD;
             the safety or efficacy of the treatment studied&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas LEVEZIEL, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poitiers University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chu de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 28, 2014</study_first_submitted>
  <study_first_submitted_qc>May 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2014</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

